Shots:
- Insilico Medicine & TaiGen have reported complete enrolment of the trial & dosing of the first patient with ISM4808 in the P-I trial to treat CKD-related anemia
- The P-I study consists of both single-ascending-dose & multiple-ascending-dose cohorts, designed to evaluate ISM4808 in healthy adults against PBO
- In Dec 2025, TaiGen gained exclusive rights to ISM4808 & related forms for further development, commercialization & sub-licensing in Greater China from Insilico, while Insilico will receive upfront, development & sales milestones, & tiered royalties, with the deal totaling tens of millions of US dollars
Ref: PRnewswire | Image: Insilico Medicine & TaiGen | Press Release
Related News: Insilico Medicine and TaiGen Biotechnology Partner for ISM4808 to Treat Anemia of Chronic Kidney Disease (CKD)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
